Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814788 · ClinicalTrials.gov registry record · Phase 2
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer
A Phase 2 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00814788 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 24 participants.
The verdict
NCT00814788, a Phase 2 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying bicalutamide and everolimus to see how well they work compared with bicalutamide in treating patients with recurrent or metastatic prostate cancer.
Interventions
- DRUG Everolimus
- DRUG Bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-12 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814788
The ClinicalTrials.gov registry entry for NCT00814788 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT00814788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814788 about?
NCT00814788 is a clinical study titled "Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is s...
What is the current status of trial NCT00814788?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-12. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00814788?
The interventions under investigation include: Everolimus (DRUG), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00814788?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.